Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08049820 in moderate to severe atopic dermatitis
NCT07216027Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Nov 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of PF-08049820 in atopic dermatitis (AD) (4 arms), sponsored by Pfizer. Primary endpoint: Percent change from baseline in Eczema Area and Severity Index total score at 12 weeks. Started Nov 2025; status: recruiting.
02
Drugs
PF-08049820
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07216027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07216027.